MY171526A - Pharmaceutical formulation for reducing frequency of urination and method of use thereof - Google Patents

Pharmaceutical formulation for reducing frequency of urination and method of use thereof

Info

Publication number
MY171526A
MY171526A MYPI2015700161A MYPI2015700161A MY171526A MY 171526 A MY171526 A MY 171526A MY PI2015700161 A MYPI2015700161 A MY PI2015700161A MY PI2015700161 A MYPI2015700161 A MY PI2015700161A MY 171526 A MY171526 A MY 171526A
Authority
MY
Malaysia
Prior art keywords
urination
pharmaceutical formulation
reducing frequency
frequency
reducing
Prior art date
Application number
MYPI2015700161A
Other languages
English (en)
Inventor
David A Dill
Original Assignee
Wellesley Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/560,665 external-priority patent/US8445011B2/en
Priority claimed from US13/800,761 external-priority patent/US20130196012A1/en
Priority claimed from US13/847,940 external-priority patent/US8703184B2/en
Application filed by Wellesley Pharmaceuticals Llc filed Critical Wellesley Pharmaceuticals Llc
Publication of MY171526A publication Critical patent/MY171526A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2015700161A 2012-07-27 2013-06-28 Pharmaceutical formulation for reducing frequency of urination and method of use thereof MY171526A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/560,665 US8445011B2 (en) 2010-07-08 2012-07-27 Delayed-release formulation for reducing the frequency of urination and method of use thereof
US13/800,761 US20130196012A1 (en) 2010-11-30 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/847,940 US8703184B2 (en) 2010-07-08 2013-03-20 Delayed-release formulation for reducing the frequency of urination and method of use thereof

Publications (1)

Publication Number Publication Date
MY171526A true MY171526A (en) 2019-10-16

Family

ID=49997724

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015700161A MY171526A (en) 2012-07-27 2013-06-28 Pharmaceutical formulation for reducing frequency of urination and method of use thereof

Country Status (16)

Country Link
US (3) US20160022615A1 (enExample)
EP (3) EP3527204A1 (enExample)
JP (4) JP2015522659A (enExample)
KR (2) KR20150048740A (enExample)
CN (4) CN104470522A (enExample)
AU (3) AU2013293489B2 (enExample)
BR (2) BR112014031306A2 (enExample)
CA (2) CA2879640A1 (enExample)
HK (4) HK1205931A1 (enExample)
IL (3) IL236028A0 (enExample)
MX (2) MX2015001188A (enExample)
MY (1) MY171526A (enExample)
RU (3) RU2015106672A (enExample)
SG (2) SG11201500578VA (enExample)
WO (2) WO2014018222A1 (enExample)
ZA (2) ZA201408993B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180054655A (ko) * 2015-09-01 2018-05-24 웰즐리 파마슈티컬스 엘엘씨 연장, 지연 및 즉시 방출 제형 제조 방법 및 용도
EP3355864A4 (en) * 2015-09-30 2019-05-22 Wellesley Pharmaceuticals, LLC COMPOSITION FOR REDUCING URINATION FREQUENCY, METHOD FOR THE PREPARATION AND USE THEREOF
AU2016331879A1 (en) * 2015-09-30 2018-05-17 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
TW201726114A (zh) * 2015-11-23 2017-08-01 魏斯理製藥公司 降低排尿頻率之組成物、其製備方法、及其應用
MX2019004191A (es) * 2017-11-07 2020-02-12 Poviva Tea Llc Composiciones de alimentos y bebidas que comprenden inhibidores de pde5.
TW202302086A (zh) 2021-02-23 2023-01-16 日商大塚製藥股份有限公司 辛那法汀(Centanafadine)醫藥調配物、及其製造和使用方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1040921B (en) * 1998-12-23 2005-12-30 Alza Corporation Dosage forms comprising porous particles
AU7360700A (en) * 1999-09-09 2001-04-10 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
EP1313478A2 (en) * 2000-08-30 2003-05-28 Lilly Icos LLC Method for treatment of migraine using pde5 inhibitors
EP1437344A4 (en) * 2001-09-28 2006-09-20 Takeda Pharmaceutical BENZENE DERIVATIVES AND PROCESS FOR THE PREPARATION AND USE THEREOF
PL372395A1 (en) * 2002-02-19 2005-07-25 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
WO2004043365A2 (en) * 2002-11-06 2004-05-27 Azaya Therapeutics, Inc. Method for treatment of premature ejaculation in humans
EP1879578A4 (en) * 2005-03-21 2009-05-13 Dov Pharmaceutical Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE
EP1741444A1 (en) * 2005-07-05 2007-01-10 Jerini AG Kinin antagonists for treating bladder dysfunction
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2007083323A2 (en) * 2006-01-23 2007-07-26 Panacea Biotec Limited. Modified release oral dosage form comprising desmopressin
WO2007113243A2 (en) * 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder
WO2009021007A1 (en) * 2007-08-06 2009-02-12 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
CN101664555A (zh) * 2008-09-02 2010-03-10 许洁 用于治疗泌尿生殖系统感染性疾病的联合药物组合物
CN102028693A (zh) * 2009-09-30 2011-04-27 梁超峰 含有5-型磷酸二酯酶抑制剂的直肠给药组合物
US9260424B2 (en) * 2009-10-26 2016-02-16 Auspex Pharmaceuticals, Inc. 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
US20120135050A1 (en) * 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US8236857B2 (en) * 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US8236856B2 (en) * 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Delayed release formulation for reducing the frequency of urination and method of use thereof
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US20120141554A1 (en) * 2010-07-08 2012-06-07 Wellesley Pharmaceuticals, Llc Delayed release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
SG11201500578VA (en) 2015-03-30
JP2015522658A (ja) 2015-08-06
AU2013293489B2 (en) 2017-09-07
HK1246203A1 (zh) 2018-09-07
JP2018039831A (ja) 2018-03-15
AU2013293488B2 (en) 2018-05-17
CN107335057A (zh) 2017-11-10
IL236028A0 (en) 2015-01-29
AU2018208765A1 (en) 2018-08-16
RU2015106762A (ru) 2016-09-20
JP2015522659A (ja) 2015-08-06
CN107661326A (zh) 2018-02-06
US20180344674A1 (en) 2018-12-06
US20160022615A1 (en) 2016-01-28
HK1205931A1 (en) 2015-12-31
IL261232A (en) 2018-10-31
CN104540505A (zh) 2015-04-22
JP2018127482A (ja) 2018-08-16
MX2015001188A (es) 2015-05-07
BR112014031306A2 (pt) 2017-06-27
MX2015001190A (es) 2015-05-07
KR20150048740A (ko) 2015-05-07
WO2014018223A1 (en) 2014-01-30
HK1250628A1 (zh) 2019-01-11
US20170100351A1 (en) 2017-04-13
EP2844241A1 (en) 2015-03-11
ZA201408993B (en) 2016-09-28
BR112015001627A2 (pt) 2017-07-04
CA2879640A1 (en) 2014-01-03
AU2013293488A2 (en) 2015-02-26
EP2877179A1 (en) 2015-06-03
IL236622A0 (en) 2015-02-26
RU2019101864A (ru) 2019-03-11
WO2014018222A1 (en) 2014-01-30
EP3527204A1 (en) 2019-08-21
EP2877179A4 (en) 2016-03-02
ZA201500459B (en) 2016-09-28
KR20150048741A (ko) 2015-05-07
CN104470522A (zh) 2015-03-25
AU2013293489A1 (en) 2015-03-12
RU2015106672A (ru) 2016-09-20
HK1205932A1 (en) 2015-12-31
AU2013293488A1 (en) 2015-02-19
CA2875818A1 (en) 2014-01-30
EP2844241A4 (en) 2015-04-29
SG11201500601QA (en) 2015-04-29

Similar Documents

Publication Publication Date Title
MY174090A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
IN2014CN00568A (enExample)
PH12017501688A1 (en) Intranasal benzodiazepine pharmaceutical compositions
IN2014DN10386A (enExample)
SG184222A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
MX2012007933A (es) Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.
ZA201401117B (en) Kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions,and methods of use thereof
IL253911A0 (en) Inhibitors of kynurenine-3-monooxygenase, pharmaceutical compositions, and methods of their use
HRP20180924T1 (hr) Sastavi za transdermalnu administraciju aktivnih sastojaka
MY173215A (en) Acetylcysteine compositions and methods of use thereof
IL230705A0 (en) Certain inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
MY173582A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
BR112014016550A8 (pt) formulação de liberação retardada para reduzir a frequência de urinação e método de uso da mesma
IN2014MN02269A (enExample)
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
MX339196B (es) Composiciones de aripiprazol y metodos para su suministro transdermico.
ZA201402820B (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
BR112014031306A2 (pt) composição farmacêutica e respectivos usos
BR112014004737A2 (pt) composto de composição de cloridrato de ambroxol e método de preparação do composto
UY34080A (es) Composición farmacéutica para administración oral que comprende fexofenadina y métodos de preparación
IN2015DN00966A (enExample)
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
IN2014DN09359A (enExample)